Comparisons of EQ-5D-Y and PedsQL in pediatric patients with mild-to-moderate chronic kidney disease in longitudinal analyses

Health and Quality of Life Outcomes

Research

Chien-Ning Hsu¹  Pei-Chen Lu²  You-Lin Tain²  Hsiang-Wen Lin³ 

[1] Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan;School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan;Division of Pediatric Nephrology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Kaohsiung, Taiwan;School of Pharmacy and Graduate Institute, College of Pharmacy, China Medical University, No. 100, Sec. 1, Jingmao Rd., 406040, Taichung City, Taiwan;Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan;Department of Pharmacy Systems, Outcomes & Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA;

关键词: Pediatrics;    Chronic kidney disease;    Health-related quality of life;    EQ-5D-Y;    PedsQL;    Longitudinal analysis;   

DOI  :  10.1186/s12955-023-02197-9

 received in 2022-11-14, accepted in 2023-10-10,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectiveTo characterize longitudinal changes and correlations between the measures of EQ-5D-Y and generic PedsQL and their associations with clinical changes in children and adolescents with mild-to-moderate chronic kidney disease (CKD).MethodsParticipants were recruited from January 2017 to September 2021 in a medical center in Taiwan. Both instruments were administered in their initial visits and every 6-month subsequent visits. Spearman’s Rho (ρ) was used to assess correlations between the scores of EQ-5D-Y and PedsQL measures in longitudinal changes. Cohen’s effect size (ES) was used to evaluate the changes of scores/subscales over time. In addition, factors associated with longitudinal changes in the score/subscales were explored.ResultsA total of 121 participants were enrolled, and 83 with ≥ 3 HRQOL measures during the 3.5 years follow-up were assessed their changes of HRQOL measures. The correlations (ρ > 0.3) appeared between the changes in the visual analog scale (VAS) of EQ-5D-Y and emotional and social subscales of PedsQL. ES was small (< 0.5) in the VAS and level-sum-score (LSS) of EQ-5D-Y scores for the clinical changes in comorbidities, while some PedsQL subscales were medium to high (0.5–0.8 or > 0.8). Hypertension, mineral bone disorder/anemia, and hyperuricemia associated with the changes in both HRQOL scores were varied by their various domains.ConclusionBoth EQ-5D-Y and PedsQL of HRQOL measures were responsive to worsened childhood CKD-related comorbidities during the follow-up; however, convergent validity between them was limited in some domains. The LSS of EQ-5D-Y showed greater changes than the VAS by comorbidity status; further comparison with utility weight is needed to determine the better performance of EQ-5D-Y.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

12951_2015_155_Article_IEq56.gif

Fig. 1